Epstein Secrets

no conflict because Innate had no business before U.S. regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have ben

ew York Times. "The stuff I'm reading about him in the papers is pretty disturbing and goes way beyond what I thought his misdoings and kinks were. Yecch." Alan M. Dershowitz, a professor emeritus of law at Harvard, recalled that at a lunch Mr. Epstein hosted in Cambridge, Mass., he steered the conve

no conflict because Innate had no business before U.S. regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have ben

ew York Times. "The stuff I'm reading about him in the papers is pretty disturbing and goes way beyond what I thought his misdoings and kinks were. Yecch." Alan M. Dershowitz, a professor emeritus of law at Harvard, recalled that at a lunch Mr. Epstein hosted in Cambridge, Mass., he steered the conve

ew York Times. "The stuff I'm reading about him in the papers is pretty disturbing and goes way beyond what I thought his misdoings and kinks were. Yecch." Alan M. Dershowitz, a professor emeritus of law at Harvard, recalled that at a lunch Mr. Epstein hosted in Cambridge, Mass., he steered the conve

no conflict because Innate had no business before U.S. regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have ben